AlphAIAlphAI — Financial news for AI agents
StockNYSE · US · USDHealthcare · Biotechnology

$IBO

IMPACT BIOMEDICAL INC.

Impact BioMedical develops and seeks to commercialize technologies for human healthcare and wellness, including drug discovery for neurological, oncologic and inflammatory diseases, biopharmaceuticals, and consumer wellness products. It operates as one business segment. Its technologies include Linebacker compounds for potential oncology, inflammatory and neurological applications; Laetose, a sugar-related formulation with potential food and therapeutic uses; functional fragrance formulations for products such as insect repellents and detergents; and Equivir, a polyphenol blend licensed for development and commercialization as an over-the-counter upper respiratory wellness offering. Impact BioMedical makes money through licensing and may pursue direct sales. It works with external partners through licensing, co-development, joint ventures and other relationships, and may receive milestone and royalty payments. Linebacker and Equivir are licensed to ProPhase Laboratories, while the company is seeking partners for Laetose and functional fragrances. Impact BioMedical is headquartered in West Henrietta, New York.

Price · $IBOvia TradingView
AI sentiment · 7d5 articles
OCT 28net (bullish − bearish)NOV 3
Bullish
1
Neutral
4
Bearish
0
Insider · 30dAll trades →

No SEC Form 4 filings for $IBO in the last 30 days.

See all $IBO insider activity →
Top stories · $IBOMore →
NOV 3·finanznachrichten.deMed

Impact Biomedical, Inc.: Impact Biomedical Inc. and Zoar Limited Announce SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business Combination

Impact Biomedical (IBO) and Zoar Limited announced the SEC's approval of their Form F-4 registration statement for a business combination. The deal, pending shareholder and NYSE American approval, will result in a combined company operating as Zoar Limited (ZOAR). A special meeting for Impact stockholders is scheduled for November 13, 2026, to vote on the proposal.

NOV 3·stocktitan.net

A vote on Impact Biomedical’s proposed merger is set for Nov. 13

Impact Biomedical (IBO) and Zoar Limited announced the SEC's approval of their business combination registration statement. A stockholder vote is scheduled for November 13, 2026. The merger, pending approval, will create a pharmaceutical company focused on active pharmaceutical ingredients. Completion is subject to stockholder and NYSE American approval, and other conditions.

SEP 16·finanznachrichten.de

Impact BioMedical, Inc.: Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley's Limited)

Impact Biomedical Inc. (IBO) filed a Form F-4 registration statement with the SEC for its proposed merger with Zoar Ltd. The merger, subject to regulatory and shareholder approvals, aims to create a pharmaceutical company focused on active pharmaceutical ingredients. The completion depends on SEC approval, shareholder votes, and NYSE American listing.

IBO sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 5 news stories mentioning IBO (IMPACT BIOMEDICAL INC.). Coverage has skewed bullish: 1 bullish, 4 neutral, and 0 bearish.

Recent IBO coverage spans mergers & acquisitions, financial news and corporate actions.

What's driving IBO

  • The effectiveness removes a major obstacle, increasing the likelihood of deal completion and potential upside for IBO if shareholders approve.

    finanznachrichten.de · Nov 3, 2026

  • The proxy filing and upcoming vote are a key milestone for the Impact‑Zoar merger.

    stocktitan.net · Nov 3, 2026

  • The filing signals progress on the merger, potentially unlocking value if approved.

    finanznachrichten.de · Sep 16, 2026

  • The reverse split aims to meet listing requirements and facilitate the pending merger, potentially improving liquidity and share price perception.

    rttnews.com · Sep 14, 2026

  • The strategic merger and anticipated listing on NYSE American could positively influence Impact BioMedical's stock, signaling growth prospects and increased investor interest.

    Benzinga · Jun 23, 2025

AlphAI scores every news story that mentions IBO with an AI model for sentiment and relevance, and aggregates insider trades from IMPACT BIOMEDICAL INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $IBO

Score
NOV 3$IBOMedfinanznachrichten.de

Impact Biomedical, Inc.: Impact Biomedical Inc. and Zoar Limited Announce SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business Combination

Impact Biomedical (IBO) and Zoar Limited announced the SEC's approval of their Form F-4 registration statement for a business combination. The deal, pending shareholder and NYSE American approval, will result in a combined company operating as Zoar Limited (ZOAR). A special meeting for Impact stockholders is scheduled for November 13, 2026, to vote on the proposal.

2 min read
NOV 3$IBOMedstocktitan.net

A vote on Impact Biomedical’s proposed merger is set for Nov. 13

Impact Biomedical (IBO) and Zoar Limited announced the SEC's approval of their business combination registration statement. A stockholder vote is scheduled for November 13, 2026. The merger, pending approval, will create a pharmaceutical company focused on active pharmaceutical ingredients. Completion is subject to stockholder and NYSE American approval, and other conditions.

1 min read
SEP 16$IBOMedfinanznachrichten.de

Impact BioMedical, Inc.: Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley's Limited)

Impact Biomedical Inc. (IBO) filed a Form F-4 registration statement with the SEC for its proposed merger with Zoar Ltd. The merger, subject to regulatory and shareholder approvals, aims to create a pharmaceutical company focused on active pharmaceutical ingredients. The completion depends on SEC approval, shareholder votes, and NYSE American listing.

2 min read
SEP 14$IBOMedrttnews.com

Impact BioMedical Announces Reverse Stock Split To Advance Merger With Zoar Ltd.

Impact BioMedical (IBO) will execute a 1-for-12.62 reverse stock split on September 23, 2026, to facilitate its merger with Zoar Ltd. The split aims to meet listing standards and support the merger, which will give IBO shareholders one Zoar share for every four IBO shares held. IBO's stock closed at $0.46 on September 11, 2026, and was at $0.43 in pre-market trading.

2 min read

Related tickers

More in Biotechnology